CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
BioPharma Dive[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.- Start
- Nov 21, 202590% CONFIDENCEsource
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.
- On Friday 21 November 2025 Eli Lilly became the first drugmaker to reach $1 trillion in market value, and the second US non-technology company after Berkshire Hathaway to do so.[1][3]
- Shares hit a record intraday high of $1,066.65 and closed at $1,059.70, up from $1,043.29 the day before.[4]
- On the 945,383,757 shares Lilly reported outstanding on 27 October 2025, that close is worth about $1.002 trillion, so Lilly finished the day above the mark; the previous day's high of $1,057.00 had fallen just short.[4][5]
- The stock had risen more than 35% in 2025 and traded at about 50 times expected earnings, on demand for tirzepatide (Mounjaro and Zepbound), which overtook Keytruda as the world's best-selling drug.[2]
- Mounjaro brought in $6.52 billion and Zepbound $3.59 billion in the third quarter of 2025, up 109% and 184%, while rival Novo Nordisk's shares had fallen nearly 45% that year.[3]
- At $1 trillion Lilly was worth two thirds of Meta, more than Walmart, and more than twice Johnson & Johnson, its closest pharma peer.[1]